CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,083 enrolled
Drug / intervention
Ibuprofen 600 mg Immediate Release/Extended Release Capletdrug
Likely dose
Ibuprofen 600 mg Immediate Release/Extended Release Capletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01789606
NCT01789606Phase 3Completed
CompareCT.gov

Ibuprofen 600 Mg Immediate Release/Extended Release (IR/ER) Caplet Self-selection, Safety And Compliance Study

Pfizer·interventional·Posted Feb 12, 2013·Updated Aug 28, 2017

In Brief

A Phase 3 clinical trial evaluating Ibuprofen 600 mg Immediate Release/Extended Release Caplet for Analgesia. Completed, enrolled 1,083 participants across 18 sites.

Detailed Summary

A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnalgesia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2013
Enrollment StartSep 24, 2012
Primary CompletionJun 3, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.4 years ago

Interventions

Ibuprofen 600 mg Immediate Release/Extended Release Capletdrug

Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.